PARP inhibitors have been studied most extensively in HSOC and triple-negative breast cancer, and have proven particularly effective against cancers associated with BRCA1 or BRCA2 mutations [28]. The gene discussed is BRCA2; the disease is triple-negative breast carcinoma.